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ABSTRACT 
Objective: To assess frequency, symptoms and outcome of pituitary apoplexy (PA) among pituitary adenoma 
patients, to gain better insight into risk factors for bleeding into pituitary adenoma, and to estimate the sequelae 
of PA by means of a matched control group. 
Method: By reviewing charts of 574 patients with pituitary adenoma we analysed incidence, symptoms and 
outcome of PA, and potential risk factors for developing PA by means of a control group (patients with pituitary 
adenoma without PA). 
Results: 42 suffered from PA; all had macroadenomas. 30/217 male (14%) and 12/179 female (7%) 
macroadenoma patients, 32/194 patients with clinically non-functioning (16.5%) and 10/202 with clinically 
active (5.0%) macroadenoma were affected. Antithrombotic therapy predisposed patients to PA (p = 0.026), 
diabetes mellitus and hypertension did not (p = 1.00). Patients with PA and pituitary adenoma patients without 
PA had similar frequencies of hypopituitarism (45 vs. 48%, p > 0.05) and visual field defects (38 vs. 55%, p > 
0.05), but ophthalmoplegia was significantly more common (76 vs. 5%, p < 0.001) in patients with PA. Nearly 
all patients were treated by surgery; most recovered from ophthalmoplegia whereas visual function improved 
only moderately. Endocrine outcome was worse in patients with PA compared to patients without PA. 
Conclusions: Male gender and characteristics of the adenoma itself (especially tumour size and tumour type) 
rather than patient's cardiovascular risk factors such as diabetes and hypertension seem to predispose to PA; 
antithrombotic therapy may also be important. 
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INTRODUCTION 
Pituitary apoplexy (PA) is defined as an acute clinical syndrome characterized by sudden onset of headaches, 
visual impairment and ophthalmoplegia due to haemorrhage with enlargement of a pituitary adenoma (1). The 
majority of reports on PA consist of single cases or small case series describing this clinically impressive 
condition; most of these reports, however, do not allow more rigorous data analysis including statistical 
evaluation. We found 11 retrospective studies in the last 29 years with a large number of patients with PA (≥16) 
(1-11). The results and essential information of these studies are summarized in table 1. To the best of our 
knowledge there are no previous case-control studies comparing potential risk factors, symptoms and outcome of 
patients with PA with pituitary adenoma patients without PA. 
The aims of our study were to assess frequency, symptoms and outcome of PA among pituitary adenoma 
patients and to analyse potential risk factors for developing PA by means of a matched control group. 
Knowledge and information about potential risk factors could help to prevent PA in pituitary adenoma (and 
incidentaloma) patients with risk factors by providing an early indication for surgery. 
SUBJECTS AND METHODS 
We performed a retrospective chart review of patients with pituitary adenoma presenting to the Division of 
Endocrinology, Department of Internal Medicine, University Hospital of Zurich. Patients were identified by a 
search in the electronic database of our Division with the following keywords: pituitary adenoma, pituitary 
tumour, hypopituitarism, prolactinoma, acromegaly and Cushing's disease. 
Charts of 574 pituitary adenoma patients from 1980 to November 2007 were reviewed. Patients who suffered an 
apoplexy in their pituitary adenoma were identified. We diagnosed PA according to the clinical definition by 
Randeva et al.: Presence of a pituitary adenoma together with at least one of the following criteria: 1. Episode of 
acute severe headaches, 2. sudden visual disturbance such as visual field defects or ophthalmoplegia (5). 
Patients with PA were compared with the total cohort of patients with pituitary adenoma during the same period. 
In order to analyse potential risk factors or associated factors for PA and to estimate sequelae of PA, we 
compared PA patients with a control group (matched case-control study-design). The control group was formed 
as follows: We assigned to each PA patient two pituitary adenoma patients without PA, who were matched for 
sex, tumour type, tumour size and age (downward order of relevance). For additional risk factors (i.e. oestrogens, 
antithrombotic therapy, diabetes mellitus, arterial hypertension, bilateral adrenalectomy, cardiac surgery and 
therapy with dopamine agonists) and outcome we compared the PA patients with the control group (5, 12, 13). 
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All patients underwent a computer tomography scan (CT) and / or magnetic resonance imaging (MRI) of the 
sellar region. In the PA group 11 patients (26%) had a CT, 23 patients (55%) had a MRI and 8 patients (19%) 
had both. In the control group 26 patients (31%) had a CT, 43 patients (51%) had a MRI and 15 patients (18%) 
had both. Tumours measuring less than 1 cm in diameter (as determined by neuroimaging) were classified as 
microadenomas, and larger tumours as macroadenomas. Tumour type was mostly determined on histology, but 
sometimes histological analysis only showed necrosis. In these cases tumour type was defined by clinical 
presentation and endocrine studies at diagnosis. Clinical presentation of gonadotropin-secreting tumours is 
similar to that of clinically non-functioning tumours. Therefore, these tumours were included under the term of 
clinically non-functioning tumours. Tumours with no further characteristics or endocrine activity were assigned 
to that group, too. Endocrine function was evaluated at the time of admittance to the hospital (before medical and 
surgical treatment), as well as 12 months after surgery. Secondary adrenal failure was defined by the perceived 
need for glucocorticoid replacement therapy with concomitant low (in the majority <200 nmol/L) serum cortisol 
levels in the early morning. Secondary hypothyroidism was defined by previously repeatedly low (usually <10 
pmol/L) serum free thyroxine levels. We defined male hypogonadism as having low serum testosterone (usually 
<12 nmol/L) and gonadotropin levels (usually FSH and LH both <2 mU/mL), and female hypogonadism as 
having amenorrhoea and low oestradiol (usually <70 pmol/L) without rising gonadotropin levels (usually FSH 
and LH both <5 mU/mL). 
Median and range were used for descriptive statistics. Fisher’s exact test was used to analyse categorical 
variables and groups. Mc Nemar test was used to analyse differences in categorical variables within the group 
(14). Multivariate logistic regression analyses adjusting for age, sex and tumour size were conducted with the 
whole group. A p-value of less than 0.05 was considered statistically significant. All statistical analyses were 
performed using SPSS Version 16.0 (SPSS Inc., Chicago, Illinois, USA). 
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RESULTS 
42 of 574 patients (7.3%) with pituitary adenoma fulfilled the diagnostic criteria for classical PA as defined 
above. In 41 of the 42 patients with classical PA, pituitary adenoma had been unknown before PA occurred. The 
median age of PA-patients was 53.5 (range 21-85) years. The median age of the control group was 50.0 (range 
23-84) years. 
Tumour size 
All 42 patients with PA had a macroadenoma. 354 patients (67%) without PA had a macroadenoma, 160 (30%) 
had a microadenoma, and 18 (3%) had an adenoma of unknown size. 
Sex 
Although women (317; 55%) presented overall more frequently with pituitary adenoma than men (257; 45%), 
PA occurred about 3 times more often in men (30/257 men; 12%) than in women (12/317 women; 4%) (odds 
ratio = 3.36, CI = 1.68 – 6.71, p < 0.001). Since PA occurred only in macroadenomas, the analysis was 
performed only in macroadenoma patients. Men with macroadenoma had a significantly increased risk for PA 
compared to women (30/217 men (14 %) and 12/179 women (7 %) with PA; odds ratio = 2.23, CI = 1.11 – 4.50, 
p = 0.022) (table 2). 
Tumour type 
The most frequent types of pituitary macroadenoma were clinically non-functioning tumours (49%) and 
prolactinomas (32%), followed by GH-secreting tumours (16%). Cushing’s disease (3%) and Nelson’s syndrome 
(0.5%) were quite rare (table 2). 
Most of the PA patients had clinically non-functioning tumours. 32/194 (16.5%) patients with clinically non-
functioning and 10/202 (5.0%) with clinically active macroadenoma developed PA, resulting in a significantly 
higher risk for PA in clinically non-functioning macroadenomas (odds ratio = 3.79, CI = 1.81 – 7.95, p < 0.001). 
Male sex and clinically non-functioning tumour type were found to be independent risk factors for PA (p < 
0.001). 
Predisposing factors 
We compared the frequencies of potential risk factors (i.e. oestrogens, antithrombotic therapy, diabetes mellitus, 
arterial hypertension, bilateral adrenalectomy, cardiac surgery and therapy with dopamine agonists) between PA 
Page 5 of 18
 6 
patients and the control group of matched patients with pituitary adenomas (table 3) (5, 12, 13). Sex, age, tumour 
size and tumour type (matched parameters) revealed no significant difference between PA and control group. 
Risk for PA was significantly elevated in patients with antithrombotic drugs (vitamin K antagonist or platelet 
inhibitors) (Odds ratio = 2.96, CI = 1.16 – 7.58, p = 0.026), but not in patients with cardiovascular risk factors 
such as diabetes mellitus (Odds ratio = 1.00, CI = 0.28 – 3.53, p = 1.00) and arterial hypertension (Odds ratio = 
0.93, CI = 0.38 – 2.29, p = 1.00). 
Remarkably none of the 42 PA patients, but 11 of the 84 control patients received dopamine agonist treatment, 
suggesting that treatment with dopamine agonists could be protective. Oestrogen treatment tended to be a risk 
factor in female patients with macroprolactinoma (n = 2 in PA group and n = 4 in control group), but for this 
potential risk factor statistical analysis was not performed due to small sample size. 
Symptoms 
Symptoms at presentation are listed in table 4. Ophthalmoplegia was significantly more frequent in the PA group 
than in the control group (Odds ratio = 64.0, CI = 18.71 – 218.93, p < 0.001). Visual field defects due to chiasma 
compression were slightly more frequent in the control group, but this result did not reach significance. 
Pituitary function 
At presentation, 45% of patients with PA, and 48% of the control group were suffering from hypopituitarism 
such as secondary adrenal failure (7% versus 10%), secondary hypothyroidism (14% versus 15%) and 
hypogonadism (43% versus 48%).  
Outcome 
39 of 42 patients with PA, and 81 of 84 control patients were treated by surgery. Two PA patients were not 
operated on their pituitary lesion due to their poor general condition. One of them died 77 days after diagnosis. 
In a third patient PA was not diagnosed until 40 days after the event at which stage surgery was postponed. In 
two control patients with macroprolactinoma treatment with dopamine agonists was initiated and surgery became 
unnecessary. One control patient with an endocrine inactive macro-incidentaloma refused surgery. 
Patients with ophthalmoplegia recovered better from their visual disturbances than patients with visual field 
defects. Nearly all patients (33/36) recovered from ophthalmoplegia without sequelae, whereas visual field 
defects persisted in about 24% of patients (15/62), both in the PA and the control group (table 5). Endocrine 
outcome was worse in patients with PA than in the control group: The frequency of hypopituitarism increased 
(from 45 at presentation to 71% during follow-up, Odds ratio = 4.7, CI = 1.30 – 25.33, p = 0.013) in the PA 
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group, while it did not change in the control group (from 48 at presentation to 55% during follow-up, Odds ratio 
= 1.5, CI = 0.68 – 3.41, p = 0.362) (table 5). Secondary adrenal failure and secondary hypothyroidism increased 
in the PA (from 7 to 55% and from 14 to 52%) as well as in the control group (from 10 to 33% and from 15 to 
44%, both p <0.001) (table 5). 
DISCUSSION 
In our retrospective series 7.3% of patients with pituitary adenoma presented with PA. In previous series the 
incidence of PA in patients with all kinds of pituitary adenoma amounted to 1.6 – 12.8% (1, 3-5, 10, 11). 
In contrast to some case-reports demonstrating that PA may occur also in small pituitary tumours, we postulate 
that a large tumour size is associated with a significantly increased risk for PA, because all of our patients with 
PA had a pituitary macroadenoma (13, 15). This finding is in line with the study of Da Motta et al., in which all 
patients had a pituitary tumour with important suprasellar extension (4). An additional major risk factor in our 
series was male gender. Men suffered significantly more frequently from PA than women, irrespective of tumour 
size. Some, but not all authors report that male sex is an independent risk factor for PA (1, 4, 5, 8, 11-13, 16, 17). 
Yet another major risk factor represents tumour type. In agreement with some but not all previously published 
series, the incidence of PA was significantly higher in our patients with clinically non-functioning tumours (1, 2, 
4-6, 8, 11, 12). Wakai et al. did not find a significant difference in the incidence of PA among different tumour 
types in their study of 560 pituitary adenoma patients and 51 PA patients (1). However, Da Motta et al., Randeva 
et al., Sibal et al. and Semple et al. reported an increased risk for PA in clinically non-functioning tumours 
(between 60% to 77%) (4-6, 8). 
Mechanisms for the development of PA are not fully understood. As discussed by Bjerre et al., blood supply to 
the anterior pituitary lobe is provided by portal vessels through the infundibulum. As the perfusion pressure is 
very low in these portal vessels, pituitary adenomas are particularly susceptible to even minor increments in 
intrasellar pressure caused by a tumour (18). Beside an elevated intrasellar pressure a further important factor for 
developing PA could be the degree and type of vascularisation of the tumour. Some authors suggest that pituitary 
adenomas can outgrow their blood supply resulting in ischemic necrosis followed by haemorrhage (5, 8). 
Cardoso and Petersen have postulated that an intrinsic vasculopathy in pituitary adenomas renders them more 
susceptible to infarction and haemorrhage (17). McCabe et al. found a markedly raised vascular endothelial 
growth factor (VEGF) mRNA expression in the tissue of clinically non-functioning tumours compared with 
other types of pituitary tumours and normal pituitaries, which could indicate that angiogenesis may be different, 
and that properties of tumour vessels could contribute to an increased risk for PA in clinically non-functioning 
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tumours (19). The results of these studies, including ours, are consistent with proposed theories on the 
pathogenesis of PA: beside male sex, large tumours and non-functioning tumour type are major risk factors for 
developing PA. 
In addition to these three major risk factors, other potential risk factors have been discussed in the literature: 
arterial hypertension, sudden changes in arterial blood pressure, diabetes mellitus, head trauma, transient 
elevations of intracranial pressure, cardiac surgery, dynamic tests of pituitary function with releasing factors, 
antithrombotic therapy, oestrogens, dopamine agonists, somatostatin analogues and radiotherapy (5, 12, 13). Of 
these risk factors we could confirm antithrombotic therapy (vitamin K antagonist or platelet inhibitors) as 
significant in our study. 
Suffering a head trauma may also be associated with an elevated risk for PA, but because of its rare occurrence 
(3 in PA group and none in control group) statistical analysis was not undertaken. The mechanism of 
posttraumatic PA is not yet fully understood. Bao et al. speculate that the change of blood flow in pituitary 
adenomas due to fluctuations of intracranial pressure and blood pressure following severe head injury leads to 
the apoplectic event in a pituitary adenoma (20). 
Similarly, statistical analysis was not possible for oestrogen treatment in female patients with prolactinoma due 
to the small sample size. Oestrogens may enhance growth and activity of prolactinoma cells, may increase 
perfusion demand and stimulate tumour vascularisation. Furthermore oestrogen treatment was reported to 
stimulate the production of VEGF in cells isolated from prolactinoma (21). 
Treatment with dopamine agonists in prolactinoma patients, by contrast, did not appear to be harmful in our 
series. Given that these agents decrease growth and activity of prolactinoma cells, we suggest that dopamine 
agonist treatment should no longer be included in the list of risk factors for PA, despite previous case reports 
suggesting the opposite (3, 12). 
Diabetes mellitus and arterial hypertension were not found to be significant risk factors for PA in our series 
suggesting that the overall cardiovascular risk profile (which predicts stroke) does not predict bleeding into a 
pituitary adenoma. 
Few studies address the long term outcome of patients with PA. In our study most patients recovered from 
ophthalmoplegia, whereas outcome in patients with visual field defects was worse. Since the three ocular motor 
cranial nerves (III, IV, and VI) are peripheral nerves, they can undergo regeneration. The optic nerve as part of 
the white matter cannot recover after axonal disruption. In the series of Onesti et al. and Bills et al. visual 
outcome was also better in patients with ophthalmoplegia than in those with visual field defects (2, 22). 
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Concerning the endocrine outcome, an event of PA may lead to irreversible loss of pituitary cells, thus leaving 
the majority of our PA patients with (at least partial) pituitary insufficiency. These observations are in line with 
some other studies (10, 23) Zayour et al. speculate that the rapid increase in intrasellar contents after 
haemorrhagic infarction of a pituitary adenoma may lead to a sudden increase in intrasellar pressure, resulting in 
ischemic necrosis of the anterior pituitary and limiting the potential for functional recovery after decompression 
(23). However, Liu et al. have found that some recovery of hormone deficiencies in their PA patients occurred 
following surgery (11). 
With increasing use of CT scans and MRI studies incidentally discovered pituitary adenomas become more 
frequent. Most pituitary adenoma patients are assigned for treatment, especially when a clinically active 
adenoma or threatening visual field defects by a large macroadenoma is found. Based on our findings, we cannot 
comment on the best management of such patients, but our observations may be helpful in management 
decisions for patients with pituitary macro-incidentalomas. According to our results, the threat of bleeding is 
highest in large, clinically non-functioning tumours in patients who are taking antithrombotic therapy for 
prevention or treatment of atherosclerosis and its complications. Therefore, among patients with pituitary 
incidentaloma, we would propose to treat those with macroadenoma and atherosclerosis by surgery even if there 
are no tumour-related signs and symptoms, to prevent PA. 
Pituitary adenomas are rarely known at the time of presentation of PA; it is therefore not surprising that all 
epidemiological data on PA derive from retrospective studies with their obvious drawbacks. Apart from being 
retrospective, another limitation of our study is its long period of time. The quality of documentation of some 
elder cases was variable, and although neuroimaging by MRI or CT scan was performed in all patients, the exact 
tumour size and tumour infiltration were not always described in sufficient detail. Some tumours were possibly 
overestimated in size because of bleeding. However, in 36 of our 42 PA patients (86%) suprasellar and/or 
parasellar extensions were documented by brain imaging studies. Among the remaining 6 PA patients, 4 had a 
tumour diameter of 2 cm and only 2 had too fragmentary data about tumour dimensions. Therefore we feel 
confident that the vast majority of our PA patients had macroadenomas before the event of PA. Without precise 
assessment of the tumour size in all patients it was not possible to prove whether large tumour size and non-
functioning tumour type were independent risk factors for PA. It can be argued that non-functioning tumours 
may be diagnosed at a later stage of disease due to late compression symptoms caused only by large tumours. 
Unfortunately, as long as we have only crude figures about tumour size (i.e. tumour size less than 1 cm or more 
than 1 cm) in some of the patients, we are unable to further determine any independency between these two risk 
factors. Moreover, concerning the endocrine status of the patients, we had only limited data on insulin 
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hypoglycaemia stress tests, considered as gold standard for determination of secondary adrenal failure. However, 
serum basal cortisol levels in the early morning may be used as first-line test in the assessment of the 
hypothalamic–pituitary–adrenal axis both preoperatively and postoperatively, as well (24). 
The strengths of our study are both the large number of included patients and the matched case-control study 
design comparing patients suffering from PA with a group of patients having comparable tumours without PA 
from the same institution and time period. 
We conclude that the risk for PA depends mainly on properties of the tumour itself (tumour size and type) and 
on the patient’s gender. Antithrombotic therapy and possibly also head trauma and oestrogen treatment in 
patients with prolactinoma may enhance or trigger such an event. Over the following months, most patients 
recovered from ophthalmoplegia but few from pituitary failure. Early diagnosis of partial pituitary failure by 
careful history and examination may help to discover pituitary adenoma in some -especially male - patients at an 
earlier stage, and thus reduce the risk for PA. 
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Table 1: Summary of previous large retrospective studies about pituitary apoplexy 
 
Total 
number of 
patients 
Cases of 
PA (n) 
Incidence 
of PA (%) essential information 
Wakai S (1981) (1) 560 51 9.1 PA is not correlated with sex, endocrine function or histological type of the adenoma, but with age. 
Bills DC (1993) (2)  37  
In stable patients with PA surgical decompression 
should be performed as soon as possible, because 
delays beyond 1 week may retard the return of visual 
function. 
Bonicki W (1993) (3) 799 39 4.9 Authors suggest surgical treatment in every case of PA to enhance neurological and endocrine recovery. 
Da Motta LA (1999) (4) 125 16 12.8 In PA surgical treatment was associated with better 
outcome than treatment with dexamethasone. 
Randeva HS (1999) (5) 982 35 3.2 
Hypertension may be an important predisposing factor 
for PA. Transsphenoidal surgery is safe and effective. 
It is indicated if there are associated abnormalities of 
visual acuity or visual fields. 
Sibal L (2004) (6)  45  
Patients with classical PA and without any or only with 
mild, non-progressive neuro-ophthalmic signs can be 
managed conservatively in the acute stage. 
Nomikos P (2004) (7)* 721 27 3.7 
Anterior pituitary function was more frequently 
preserved, normalized or even improved after 
transsphenoidal surgery compared to transcranial 
surgery in patients with non-functioning pituitary 
adenomas. 
Semple PL (2005) (8)  62  
Emergency surgery is required in patients with a 
diminished level of consciousness, deteriorating vision 
or sudden onset of blindness. Isolated cranial nerve 
palsies may be successfully managed conservatively. 
Nielsen EH (2006) (9)* 192 41 21 
PA occurs more frequently than usually assumed. In 
patients operated on for non-functioning pituitary 
adenoma, survival is independent of the occurrence of 
PA. 
Dubuisson AS (2007) (10) 1540 24 1.6 
PA is a rare event. Complete recovery is possible if 
the diagnosis is rapidly obtained and adequate 
management is initiated in time. Surgical results are 
very satisfactory in the majority of cases. 
Liu ZH (2010) (11) 262 25 9.5 
Classical PA is a rare event. The incidence of 
subclinical PA is higher than classical PA. Patients 
with classical PA have a higher mean age and most 
patients were male (68%). Visual improvement is 
better in subclinical PA than in classical PA. In both 
classical and subclinical PA anterior pituitary function 
is able to recover. 
n = number of patients, PA = pituitary apoplexy 
* In these studies only patients with non-functioning pituitary adenomas were included. 
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 Table 2 : Tumour-type 
macroadenoma patients with PA without PA Total 
 n          % n          % n          % 
total 42 100 354 100 396 100 
men 30 71 187 53 217 55 
women 12 29 167 47 179 45 
non-functioning 32 76 162 45 194 49 
prolactinoma 7 17 119 34 126 32 
GH-secreting 1 2 62 18 63 16 
Cushing’s disease 1 2 10 3 11 3 
Nelson’s syndrome 1 2 1 1 2 1 
n = number of patients, PA = pituitary apoplexy 
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 Table 3: Predisposing factors for PA 
patients with PA control group p-value ** 
 n                    % n                    %  
total 42 100 84 100  
antithrombotic therapy 12 29 10 12 0.026 
diabetes mellitus 4 10 8 10 1.00 
arterial hypertension 9 21 19 23 1.00 
dopamine agonists 0 0 11 13 - 
oestrogens (depot injection)* 2 100 0 0 - 
bilateral adrenalectomy 1 2 0 0 - 
cardiac surgery 1 2 0 0 - 
head trauma 3 7 0 0 - 
n = number of patients, PA = pituitary apoplexy 
 
*These calculations include only women with macroprolactinoma (n = 2 and 4 respectively) 
 
**Statistical analysis done by Fisher’s exact test 
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 Table 4: Symptoms at presentation 
patients with PA control group p-value** 
 n                       % n                       %  
total 42 100 84 100  
ophthalmoplegia 32 76 4 5 <0.001 
visual field defects 16 38 46 55 0.091 
chronic headaches 5 12 20 24 0.156 
amenorrhoea* 6 50 9 38 0.499 
galactorrhoea* 2 17 4 17 1.00 
hypopituitarism at presentation 19 45 40 48 0.851 
n = number of patients, PA = pituitary apoplexy 
 
*These calculations include only women (n = 12 or 24 respectively) 
 
** Statistical analysis done by Fisher’s exact test 
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 Table 5: Visual and endocrine outcome 
patients  with PA (n = 42) control group (n = 84) PA vs. control group 
  n               % n               % p-value** 
at presentation 32 76 4 5 <0.001 
ophthalmoplegia 
outcome 3 7 0 0 - 
present. vs. outc.: p-value*** n.a. n.a.  
at presentation 16 38 46 55 0.091 
visual field 
defects 
outcome 2 5 13 15 0.142 
present. vs. outc.: p-value*** n.a. n.a.  
at presentation 19 45 40 48 0.851 
hypopituitarism* 
outcome 30 71 46 55 0.084 
present. vs. outc.: p-value*** 0.013 0.362  
at presentation 3 7 8 10 0.750 
secondary 
adrenal failure 
outcome 23 55 28 33 0.034 
present. vs. outc.: p-value*** n.a. <0.001  
at presentation 18 43 40 48 0.705 
hypogonadism 
outcome 23 55 39 46 0.451 
present. vs. outc.: p-value*** 0.332 1.000  
at presentation 6 14 13 15 1.000 
hypothyroidism 
outcome 22 52 37 44 0.450 
present. vs. outc.: p-value*** n.a. <0.001  
at presentation 1 2 0 0 - 
diabetes insipidus 
outcome 1 2 8 10 0.270 
present. vs. outc. p-value*** n.a. n.a.  
n = number of patients, n.a. = McNemar test not applicable, outc. = outcome, PA = pituitary apoplexy, present. = at 
presentation, vs. = versus 
 
*The term “hypopituitarism” includes any (including partial) pituitary failure such as ACTH, TSH or gonadotropin deficiency. 
 
** Statistical analysis done by Fisher’s exact test 
 
***Statistical analysis done by McNemar test 
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